ENB-106 is under clinical development by Ennovabio and currently in Phase III for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase III drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how ENB-106’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ENB-106 overview
ENN-106 is under development for the treatment of diabetic retinopathy (DR), diabetic macular edema (DME), cancer, non-alcoholic steatohepatitis (NASH) and cardiac surgery-associated acute kidney injury (CSA-AKI). The drug candidate is administered through oral route. It is being developed based on eSTEM systems biology platform.
It was under development for unspecified cancer.
Ennovabio overview
Ennovabio, a pharmaceutical company that focuses on creating drugs targeting brain glioma. The company is headquartered in China.
For a complete picture of ENB-106’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.